Cargando…

PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model

Detalles Bibliográficos
Autores principales:	Mu, Songlin, Liang, Zhijuan, Wang, Yongmei, Chu, Wendi, Chen, Yi‐Li, Wang, Qi, Wang, Guifeng, Wang, Chunhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076010/ https://www.ncbi.nlm.nih.gov/pubmed/35522941 http://dx.doi.org/10.1002/ctm2.754

Ejemplares similares

HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities
por: Chu, Wendi, et al.
Publicado: (2022)

Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
por: Zhong, Zhenwei, et al.
Publicado: (2022)

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker
por: Chen, Yuning, et al.
Publicado: (2021)

A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy
por: Chen, Yi-Li, et al.
Publicado: (2021)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer
por: Liu, Xiaoyue, et al.
Publicado: (2022)

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

A BIVALENT TIM-3/PD-1 BISPECIFIC ANTIBODY FOR THE TREATMENT OF PD-1 ANTIBODY RESISTANT OR REFRACTORY SOLID TUMORS
por: Luan, Yan, et al.
Publicado: (2023)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
por: Li, Tianye, et al.
Publicado: (2023)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants
por: Ou, Jianxia, et al.
Publicado: (2022)

Design and Production of Bispecific Antibodies
por: Wang, Qiong, et al.
Publicado: (2019)

A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer
por: Sun, Zu-Jun, et al.
Publicado: (2017)

Analgesic effects of nerve growth factor‐directed monoclonal antibody on diabetic neuralgia in an animal model
por: Dong, Xingchen, et al.
Publicado: (2022)

PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma
por: Yang, Zhenlin, et al.
Publicado: (2022)

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
por: Jiang, Haiping, et al.
Publicado: (2021)

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
por: Wang, Peipei, et al.
Publicado: (2021)

Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT
por: Diong, SJ J., et al.
Publicado: (2023)

Production of Native Bispecific Antibodies in Rabbits
por: Wang, Wei, et al.
Publicado: (2010)

A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT
por: Fu, Zhihao, et al.
Publicado: (2021)

A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers
por: Hosseinkhani, Negar, et al.
Publicado: (2021)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

Structural and functional characterization of a monoclonal antibody blocking TIGIT
por: Jeong, Bo-Seong, et al.
Publicado: (2022)

Dynamic Expressions of TIGIT on Splenic T Cells and TIGIT-Mediated Splenic T Cell Dysfunction of Mice With Chronic Toxoplasma gondii Infection
por: Li, Haoran, et al.
Publicado: (2021)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities
por: Cui, Xiaopei, et al.
Publicado: (2021)

Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment
por: Wang, Rongjuan, et al.
Publicado: (2023)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

The Ratio of CD226 and TIGIT Expression in Tfh and PD-1(+)ICOS(+)Tfh Cells Are Potential Biomarkers for Chronic Antibody-Mediated Rejection in Kidney Transplantation
por: Fan, Ji-wen, et al.
Publicado: (2022)

TIGIT Can Exert Immunosuppressive Effects on CD8(+) T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro
por: Zhang, Changkun, et al.
Publicado: (2020)

A human IgE bispecific antibody shows potent cytotoxic capacity mediated by monocytes
por: Vukovic, Natasa, et al.
Publicado: (2022)

TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma
por: Raphael, Itay, et al.
Publicado: (2021)

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
por: Niu, Mengke, et al.
Publicado: (2023)

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
por: Pang, Xinghua, et al.
Publicado: (2023)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
por: Martinez, Marina, et al.
Publicado: (2021)

Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade
por: Pearce, Hayden, et al.
Publicado: (2023)

The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients
por: Pawłowska, Anna, et al.
Publicado: (2022)

Dual targeting of RANKL and PD‐1 with a bispecific antibody improves anti‐tumor immunity
por: Dougall, William C., et al.
Publicado: (2019)

Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1
por: Mohan, Nishant, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mm1ujnv1tg2nkdmiku5qi89hc9